Business
Earth Science Tech Announces New Wholly Owned Subsidiary, Cannabis Therapeutics Inc., to Develop & Launch its Cannabis Cannabinoid-Based Drugs & Nutraceuticals Using its Cannabinoid-Cannabidiol (CBD) Patent, IP and Technology
Earth Science Tech Announces New Wholly Owned Subsidiary, Cannabis Therapeutics Inc., to Develop & Launch its Cannabis Cannabinoid-Based Drugs & Nutraceuticals Using its Cannabinoid-Cannabidiol (CBD) Patent, IP and Technology.
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\nHollywood, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) (\"ETST\" or \"the Company\"), an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals is pleased to announce its new wholly owned subsidiary, Cannabis Therapeutics, Inc. will be releasing new Cannabinoid-based Drugs and Nutraceuticals. \n\nCannabis Therapeutics, Inc. will begin by inventing & launching Two (2) New Cannabinoid-based Pharmaceutical drugs and Three (3) New Advanced Cannabinoid-based Nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, Invention, Technology and future Technology. ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015.\n\n\nCannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid (phytocannabinoids and synthetic cannabinoids) research and development for a broad line of cannabis cannabinoid-based therapeutic pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company has appointed Dr. Michel Aube as the CEO and Nickolas Tabraue as the President of Cannabis Therapeutics, Inc.\n\n\nCEO of Cannabis Therapeutics, Inc., Dr. Michel Aube, stated, “I am very enthusiastic about Cannabis Therapeutics position in the cannabis industry to become a leader in cannabinoid research and development. Our imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceutical...